Presently, however, only two monoclonal antibodies (mAbs), tocilizumab (anti–IL-6R) and siltuximab (anti–IL-6), have been approved in the US for the treatment of rheumatoid arthritis (RA) and Castleman's disease respectively, but not for cancer. Here, IL6R is linked to Castleman disease.